NCT04586907View on ClinicalTrials.gov

A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

85

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions

HealthyType 2 Diabetes Mellitus

Interventions

DRUG

LY3537021

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY